News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merrion Pharmaceuticals, Inc. Announces License Agreement With Novo Nordisk A/S (NVO) to Develop Oral Formulation of GLP-1 Receptor Agonist(s) -- Novo Nordisk Makes Equity Investment in Merrion



1/16/2009 7:05:03 AM

DUBLIN, Ireland, Jan. 16, 2009 (GLOBE NEWSWIRE) -- Merrion Pharmaceuticals (IEX:MERR) and Novo Nordisk A/S (NYSE:NVO - News), a world leader in diabetes, have entered into a Development and License Agreement to develop and commercialise oral formulations of a Novo Nordisk proprietary GLP-1 receptor agonist, using Merrion's proprietary GIPET(r) technology. This is the second license agreement between the two companies concerning Merrion's GIPET(r) technology -- the first agreement for the development of oral insulin analogues was signed in November 2008.

Read at GlobeNewswire


comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES